What EBITDA margins do you expect from the Animal Health business?

The margin profile once we reach that operational leverage will be 20% plus EBITDA margins for the Animal Health business.

What would it take for the Crop Protection business to get back on trajectory, and what should we expect on a three-year basis?

The end customers are not doing well, innovation is not accelerating; we are expecting very marginal growth, mid to high single digit going forward, and are not investing significant new capital. We are managing with strict capital allocation and financial discipline.

Given pharma and Animal Health are higher-margin, shouldn't EBITDA growth and margins be better than the 25-30% growth guidance?

This is a transition year; FDA remediation costs are substantial and are hitting fixed costs, depressing EBITDA. Once remediation goes away by end of this year, next year onwards margins will improve substantially.

How should we look at incremental revenue in FY28 post US FDA clearance?

We have pending filings awaiting FDA approval; once approval comes, those filings will be done and will ramp up revenues in FY28. Overall growth will accelerate over FY27.

Are you getting contracts revised to pass through input cost increases in Crop Protection?

It's a mixed bag; some contracts have pass-through but where competitive pressure from China exists, customers partially compensate. In Q1 we were impacted by ₹7-8 Cr of raw material increase. We hope prices normalize by end of Q2 if oil prices drop, but geopolitical volatility makes it uncertain.

What gives you confidence that you will clear the US FDA re-inspection this year?

We are in continuous dialogue with the FDA, feedback indicates we are moving in the right direction. Several global regulatory bodies and 86 customer audits have re-approved us. Innovator customers are handholding us in the remediation process.

Hikal Q1 FY27 Earnings Call — Analysis (NSE: HIKAL)

Hikal Q1 FY27 revenue ₹403 Cr, EBITDA margin 9.2% amid US FDA remediation; management guides 14-16% FY27 revenue growth and 25-30% EBITDA growth as pharma recovery and new ventures ramp up.

12 Aug 2026 · Analysis by Alpha Inflection

Result quality: watch — Loss narrowed. Management sentiment: optimistic.

The take

Q1FY27 Revenue ₹403 Cr . New guidance — FY30 animal health revenue target ₹400 Cr plus . New story: US FDA remediation and regulatory recovery .

Results

Revenue ₹403 Cr, EBITDA ₹37 Cr (9.2% margin), PAT -₹7 Cr; Pharma revenue ₹233 Cr, Crop ₹170 Cr; sequential volume improvement but margin hit from higher raw material costs and FDA remediation expenses.

Financial highlights

Hikal Q1 FY27 reported figures
Metric	Value	Change	Basis
Revenue	₹403 Cr		none · Q1FY27
EBITDA	₹37 Cr		none · Q1FY27
EBITDA margin	9.2%		none · Q1FY27
PAT	-₹7 Cr		none · Q1FY27
Pharma revenue	₹233 Cr		none · Q1FY27
Crop revenue	₹170 Cr		none · Q1FY27
Capex	₹45 Cr		none · Q1FY27
Net debt	₹685 Cr		point_in_time · FY26 · Mar-26; reduced from ₹815 Cr in FY24
Debt-to-equity	0.53	-0.03	qoq · Q1FY27 · vs 0.56 in Mar-26

Guidance

FY27 revenue growth guided at 14-16%, EBITDA growth 25-30% YoY; H2 recovery expected to accelerate, Q2 to see substantial YoY growth; Animal Health target ₹400+ Cr revenue by FY30 with >20% EBITDA margins.

What management committed to

US FDA re-inspection [of Hikal's facilities] towards the end of FY27. — FY27
DMF filing rate to increase to 5-6 per year [from 2-3 historically]. — 5-6 per year
[Personal Care segment] revenue by end of FY27. — FY27
[Animal Health] business to reach ₹400+ Cr revenue by FY30. — ₹400 crores plus, FY30
[Animal Health] business EBITDA margins >20% once operational leverage is achieved [implied by FY30]. — 20% plus, FY30
FY27 consolidated revenue growth in the range of 14% to 16% YoY. — 14% to 16%, FY27
FY27 consolidated EBITDA growth in the range of 25% to 30% YoY. — 25%-30%, FY27
Q2 FY27 to show substantial YoY growth in revenues and EBITDA. — substantial growth, Q2FY27
H2 FY27 momentum to improve, with recovery in regulated markets and increasing CDMO contribution raising margins. — H2FY27
FY28 will be a substantially better year than FY27, with EBITDA improvement due to removal of FDA remediation costs. — FY28
Pharma division CAGR of 18% to 19% going forward. — 18% to 19%
Crop Protection division will see marginal growth, mid to high single digit going forward. — mid to high single digit

Key themes

Recovery, diversification, and FDA remediation

How the narrative shifted

US FDA remediation and regulatory recovery: Management positions the warning letter resolution as the key unlock for pharma growth, emphasizing rigorous remediation, external validations, and no customer losses.
Diversification into Animal Health and Personal Care: These emerging verticals are framed as higher-margin growth platforms that will shift the revenue mix away from crop, targeting 70-80% pharma-allied revenue in 2-3 years.
Crop Protection margin pressure from China and geopolitics: Global overcapacity and Chinese pricing dominance, compounded by geopolitical raw material cost spikes, are limiting margin recovery; the company is de-emphasizing crop capex.
Operating leverage from past heavy capex cycle: Large capex in recent years (~₹900 Cr) is now being redirected/retooled for pharma and Animal Health, with the benefit expected to flow through as fixed cost absorption improves.
CDMO-led growth and customer stickiness: Pharma and Animal Health CDMO pipelines are deepening, with repeat orders, long-term contracts, and high-touch innovator relationships de-risking revenue.
Capital allocation discipline and balance sheet strengthening: Management stresses selective investment, internal accrual funding, and debt reduction, signaling a shift from build-out to harvest mode.
Demand recovery cautious amid just-in-time ordering: Channel inventories normalized but distributors still buying need-based rather than restocking, making the recovery steady but gradual.

Operational commentary

cGMP pilot plant and new pilot plant in Panoli commissioned, expected to increase DMF filing rate from 2-3 to 5-6 per year, accelerating product development and pipeline strength.
US FDA remediation on track; management expects re-inspection by end of FY27; three major international regulatory bodies and 86 customer audits conducted and facilities re-approved, with zero customer losses in the last 12 months.
Animal Health business scaling: revenue crossed ₹100 Cr in FY26, guided to reach ₹400+ Cr by FY30 with >20% EBITDA margins; new NCEs and advanced intermediates progressing through development to commercialization; US EPA and Canada PMRA filings completed for one molecule.
Personal Care segment launched: dedicated multi-purpose line commissioned at Panoli, first commercial production commenced, revenue expected by end of FY27; target ₹200 Cr revenue in 3 years with >20% EBITDA margins, leveraging existing manufacturing and regulatory capabilities.
Crop Protection: global channel inventories normalized, volume recovery underway but pricing under pressure from Chinese overcapacity and geopolitical raw material cost spikes (₹7-8 Cr raw material impact in Q1); no significant new capital allocated to crop, focus on cash flow, cost efficiency, and selective customer onboarding.
Pharma CDMO pipeline strengthening: 8-9 molecules in development, repeat campaign orders from innovators; added 4 business development professionals in Japan, North America, Europe; discussions with a leading Japanese innovator progressing well.
Pharma capacity utilization at 55-60% in Q1 due to planned shutdown for FDA remediation, expected to improve as remediation completes and commercial volumes ramp up.
Capital allocation discipline: of ~₹900 Cr capex over 4 years, growth capex retooled impaired agrochemical plant to multi-purpose pharma/Animal Health facility, reducing execution timelines by 12 months; new Animal Health dedicated site already generating revenue; R&D upgraded with high-potency lab and pilot plants.

Analyst Q&A

Q. What EBITDA margins do you expect from the Animal Health business?
The margin profile once we reach that operational leverage will be 20% plus EBITDA margins for the Animal Health business.
Q. What would it take for the Crop Protection business to get back on trajectory, and what should we expect on a three-year basis?
The end customers are not doing well, innovation is not accelerating; we are expecting very marginal growth, mid to high single digit going forward, and are not investing significant new capital. We are managing with strict capital allocation and financial discipline.
Q. Given pharma and Animal Health are higher-margin, shouldn't EBITDA growth and margins be better than the 25-30% growth guidance?
This is a transition year; FDA remediation costs are substantial and are hitting fixed costs, depressing EBITDA. Once remediation goes away by end of this year, next year onwards margins will improve substantially.
Q. How should we look at incremental revenue in FY28 post US FDA clearance?
We have pending filings awaiting FDA approval; once approval comes, those filings will be done and will ramp up revenues in FY28. Overall growth will accelerate over FY27.
Q. Are you getting contracts revised to pass through input cost increases in Crop Protection?
It's a mixed bag; some contracts have pass-through but where competitive pressure from China exists, customers partially compensate. In Q1 we were impacted by ₹7-8 Cr of raw material increase. We hope prices normalize by end of Q2 if oil prices drop, but geopolitical volatility makes it uncertain.
Q. What gives you confidence that you will clear the US FDA re-inspection this year?
We are in continuous dialogue with the FDA, feedback indicates we are moving in the right direction. Several global regulatory bodies and 86 customer audits have re-approved us. Innovator customers are handholding us in the remediation process.

View source

Research and educational content only. Not investment advice.